RBC Capital reiterates Legend Biotech stock rating on pharma interest By Investing.com

RBC Capital reiterated an Outperform rating on Legend Biotech with a $62 price target, citing Eli Lilly’s $3.25 billion upfront acquisition of Kelonia as validation of the BCMA CAR-T market. Legend Biotech reported Q4 2025 revenue of about $306 million, ahead of the $288 million estimate, and EPS of $(0.08) versus $(0.10) expected, while Carvykti worldwide sales rose to $597 million in Q1 2026. The stock has gained roughly 30% over the past month, and analysts remain constructive despite mixed price-target adjustments.

Analysis

The key read-through is not simply that a large pharma deal validates BCMA CAR-T, but that it raises the implied option value of Legend’s platform relative to its current equity value. When a strategic acquirer pays up for an early in-vivo CAR-T asset, public-market investors usually re-rate the most advanced commercial peer first, then the platform assets second; that creates a two-stage bid that can extend well beyond the initial headline reaction. The market may still be underestimating how much of LEGN’s valuation is now anchored in pipeline optionality rather than just Carvykti cash flows.

The bigger second-order effect is competitive compression: if in-vivo CAR-T is perceived as the next battleground, capital and partnering pressure shift toward companies that can show cleaner manufacturability, broader target expansion, and faster time-to-clinic. That is constructive for LEGN near term, but it also raises the bar for execution because any delay in its own in-vivo data window would likely trigger multiple contraction after the current momentum trade exhausts itself. JNJ is indirectly exposed because Carvykti remains the bridge asset; stronger sales support the story, but they also make the market more sensitive to any sign that next-gen assets are slipping.

The contrarian setup is that the move may be more crowded than it looks: the stock has already repriced on both analyst upgrades and M&A comps, so incremental upside now depends on data delivery, not narrative. The most likely reversal trigger is not fundamental deterioration in Carvykti, but a lack of fresh catalysts over the next 1-2 quarters, which would allow investors to fade the valuation gap before the 2H26 in-vivo readout. In that sense, the near-term trade is a momentum continuation, while the medium-term trade is a catalyst-risk short if expectations keep outrunning timelines.

Key Decisions for Investors

• Stay long LEGN tactically for 4-8 weeks while M&A comp rerating is still flowing through; use a tight trailing stop because the setup is sentiment-heavy and can unwind quickly if the market stops rewarding peer multiple expansion.
• For new money, prefer a call spread in LEGN over outright stock exposure into the next catalyst window: it captures upside from continued rerating while capping downside if the post-headline fade starts before 2H26 data visibility improves.
• Pair trade idea: long LEGN / short a basket of slower-moving large-cap oncology incumbents over 1-3 months to express platform scarcity; the thesis is that capital will continue rotating toward names with direct exposure to next-gen cell therapy optionality.
• For longer-dated expression, consider buying a put spread in LEGN 3-6 months out only on a rally extension; the risk/reward improves if the stock runs ahead of actual clinical milestones and the market begins discounting execution risk.
• Hold JNJ as the lower-volatility way to own Carvykti momentum, but do not chase fresh longs here solely on the acquisition headline; the better risk/reward remains in the small-cap platform leverage rather than the diversified sponsor.